FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 615 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Raises Key Issues on Cancer Prevention and Care at the WHO Executive Board Meeting Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French MOST POPULAR Significant Benefits of Nivolumab Plus Cabozantinib Over Sunitinib in Previously Untreated... March 5, 2021 FDA Grants Accelerated Approval to Sotorasib for KRAS G12C-mutated NSCLC June 4, 2021 Mortality From PSA-Detected Localised Prostate Cancer Remains Very Low Regardless of... March 21, 2023 49-Year-Old Breast Cancer Patient Grateful She Didn’t Wait Until 50 for... June 7, 2019 Load more HOT NEWS 2025 ESMO Society Award recipients announced FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or... Integrating Geriatric Assessment into Cancer Care: A Conversation with Dr. Supriya... Young Mom Of Two Survived Breast Cancer, Heart Failure, And Two...
